All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: A population-based, open cohort study

GLP1a treatment in a real-world setting may confer additional mortality benefit in patients with T2DM irrespective of their baseline CVD risk, age or baseline glycated haemoglobin and was sustained over the observation period.